Idera Pharmaceuticals Inc.

Idera Pharmaceuticals and Merck & Co., Inc. Extend Research Collaboration for Agonists of Toll-like Receptors as Vaccine Adjuvants.
Vaccine Weekly; 12/9/2009; 1099 words; ...Mental Health, Merck & Company Inc., Oncology, Pharmaceutical, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Therapy, Treatment, Vaccines, Idera Pharmaceuticals Inc. This article was prepared by Vaccine Weekly editors...

Idera Pharmaceuticals Announces Termination of Asthma and Allergy Research Collaboration Agreement.
Biotech Week; 12/9/2009; 780 words; ...Marketing and Licensing Agreements, Novartis AG, Pharmaceutical, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Research, Science, Therapy, Treatment, Idera Pharmaceuticals Inc. Idera Pharmaceuticals Inc. This article...

Idera Pharmaceuticals Appoints Rahul Jasuja, Ph.D., Vice President of Corporate Development.
Business Wire; 12/4/2009; 1038 words; ...CAMBRIDGE, Mass. -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA...capital markets to Idera," commented...concerning Idera Pharmaceuticals, Inc. that involve...products based on Idera's technology...of Merck & Co. Inc. will be successful...

FORM 8-K: IDERA PHARMACEUTICALS ANNOUNCES TERMINATION OF MATERIAL DEFINITIVE AGREEMENT
US Fed News Service, Including US State News; 11/28/2009; 531 words; ...specified in its charter is Idera Pharmaceuticals, Inc. State of Incorporation...Material Definitive Agreement. Idera Pharmaceuticals, Inc. (the "Company") received...from Novartis International Pharmaceutical Ltd. ("Novartis") that...

TLR Platform Wins Bigger Deal with Merck, While Novartis Bails.
BIOWORLD Today; 11/26/2009; 1256 words; ...drugmaker Novartis AG is handing back rights to Idera Pharmaceuticals Inc.'s Toll-like receptor-targeted compounds aimed at respiratory disease, while Merck & Co. Inc. and Idera agreed to extend their research agreement covering...